Krishnan Nandabalan - 06 Apr 2023 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: BTAI
Reported as of: 06 Apr 2023
Net transaction value: -$1,014,600
SEC form: 4
Accepted by SEC: 10 Apr 2023, 18:20:14 UTC
Prior SEC filing: 06 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Krishnan Nandabalan

Key filing fact

Krishnan Nandabalan filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 10 Apr 2023.

Key facts

This page summarizes Krishnan Nandabalan's Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Apr 2023, 18:20.

Change

Previous filing in this sequence was filed on 06 Jan 2023.
Current net transaction value: -$1,014,600.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BTAI transaction

Common Stock

Options Exercise

Transaction value: $24,600
Shares: +60,000
Change %
Price: $0.4100^*
Shares after: 60,000
Date: 06 Apr 2023
Ownership: Direct

BTAI transaction

Common Stock

Sale

Transaction value: $1,039,200
Shares: -60,000
Change %: -100%
Price: $17.32
Shares after: 0
Date: 06 Apr 2023
Ownership: Direct
Footnotes: F1, F2

BTAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,546,750
Date: 06 Apr 2023
Ownership: See footnote
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BTAI transaction Derivative

Stock Options

Options Exercise

Transaction value: $0
Shares: -60,000
Change %: -17%
Price: $0.000000
Shares after: 294,000
Date: 06 Apr 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $0.4100
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The sale reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022.

Footnote F2

The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $17.03 to $17.70. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Footnote F3

These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Holdings"). By virtue of the Reporting Person's relationship with BioXcel LLC and Holdings, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Footnote F4

The options are fully vested and exercisable.